Nyxoah (NYXH) Price & Analysis

Compare

119 Followers

NYXH Stock Chart & Stats

Day’s Range― - ―

52-Week Range$5.55 - $11.87

Previous CloseN/A

Volume100.61K

Average Volume (3M)123.70K

Market Cap

$241.48M

Enterprise Value$220.85M

Total Cash (Recent Filing)N/A

Total Debt (Recent Filing)N/A

Price to Earnings (P/E)―

Beta0.93

Next Earnings

Nov 13, 2025

EPS Estimate

-0.68

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.64

Shares Outstanding37,429,264

10 Day Avg. Volume141,222

30 Day Avg. Volume123,697

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap0.91

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

$13.58

Price Target Upside120.10% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering5

Bulls Say, Bears Say

Bulls Say

Clinical PerformanceNyxoah announced that 82.0% of patients who completed a polysomnography at 12 months had an AHI below 15 and that 67.4% of patients had an AHI below 10.

Market OpportunityThe target market for Genio in the U.S. is approximately 510,000 patients, representing an annual total addressable market of approximately $10 billion.

Regulatory ApprovalThe FDA has issued an Approvable Letter for Nyxoah's Genio system, indicating a positive step towards full market approval.

Bears Say

Regulatory ChallengesThere is an issue with the FDA’s acceptance of data regarding manufacturing processes, delaying the anticipated approval.

Sales Performance4Q24 Genio sales were below estimates, with reported sales of €1.3M compared to an expected €2.4M.

Nyxoah News

Closing Bell Movers: Palo Alto Networks jumps 5% on Q4 earnings beat

In the opening hour of the evening session, U.S. equity futures are up slightly, with S&P 500, Nasdaq...

10d ago

Nyxoah reports Q2 EPS (EUR 0.55) vs. (EUR 0.43) last year

Reports Q2 revenue EUR 1.34M vs. EUR 771,000 last year. “This FDA approval represents a historic milestone for...

11d ago

NYXH

Nyxoah reports preliminary Q2 revenue EUR 1.3M

Reports preliminary Q2 operating expenses EUR 20.7M. “We are pleased with the growth we saw in the second...

18d ago

NYXH

Nyxoah receives FDA approval for Genio system

Nyxoah (NYXH) announced that the FDA has approved the Genio system for a subset of patients with moderate...

21d ago

NYXH

Nyxoah’s Genio System Gains FDA Approval

Nyxoah Sa ( ($NYXH) ) has released its Q2 earnings. Here is a breakdown of the information Nyxoah...

10d ago

NYXH

Nyxoah Launches Genio System in U.S. Following FDA Approval

Nyxoah ( ($NYXH) ) has provided an update. On August 18, 2025, Nyxoah SA announced its financial and...

10d ago

NYXH

Is NYXH a Buy, Before Earnings?

Nyxoah Sa (NYXH) is scheduled to report 2nd quarter earnings on 08/18/2025, after the market closes. Regarding Q2...

13d ago

NYXH

Nyxoah Gains FDA Approval for Genio System in U.S.

An announcement from Nyxoah ( ($NYXH) ) is now available. On August 8, 2025, Nyxoah announced the FDA...

18d ago

NYXH

Nyxoah’s DREAM Study Data Published, Highlighting Genio® System’s Efficacy

Nyxoah ( ($NYXH) ) has shared an announcement. On July 28, 2025, Nyxoah announced the publication of data...

1M ago

NYXH

Nyxoah publishes DREAM study data in Journal of Clinical Sleep Medicine

Nyxoah (NYXH) announced that data from its DREAM pivotal study was published online in the Journal of Clinical...

1M ago

NYXH

Nyxoah’s Innovative Approach to Sleep Apnea: A Clinical Study Update

Nyxoah Sa (($NYXH)) announced an update on their ongoing clinical study. Nyxoah S.A. is conducting a multicenter study...

1M ago

NYXH

Nyxoah SA Announces New Share Issuance to Strengthen Financial Structure

An announcement from Nyxoah ( ($NYXH) ) is now available. On June 27, 2025, Nyxoah SA announced the...

2M ago

NYXH

Nyxoah Announces Change in Shareholder Voting Rights

An update from Nyxoah ( ($NYXH) ) is now available. On May 30, 2025, Nyxoah SA announced that...

3M ago

NYXH

Nyxoah SA Updates Share Capital and Voting Rights

Nyxoah ( ($NYXH) ) has shared an update. On May 23, 2025, Nyxoah SA announced the issuance of...

3M ago

NYXH

NYXH FAQ

What was Nyxoah’s price range in the past 12 months?

Nyxoah lowest stock price was $5.55 and its highest was $11.87 in the past 12 months.

What is Nyxoah’s market cap?

Nyxoah’s market cap is $241.48M.

When is Nyxoah’s upcoming earnings report date?

Nyxoah’s upcoming earnings report date is Nov 13, 2025 which is in 76 days.

How were Nyxoah’s earnings last quarter?

Nyxoah released its earnings results on Aug 18, 2025. The company reported -$0.642 earnings per share for the quarter, beating the consensus estimate of -$0.663 by $0.021.

Is Nyxoah overvalued?

According to Wall Street analysts Nyxoah’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Nyxoah pay dividends?

Nyxoah does not currently pay dividends.

What is Nyxoah’s EPS estimate?

Nyxoah’s EPS estimate is -0.68.

How many shares outstanding does Nyxoah have?

Nyxoah has 37,429,264 shares outstanding.

What happened to Nyxoah’s price movement after its last earnings report?

Nyxoah reported an EPS of -$0.642 in its last earnings report, beating expectations of -$0.663. Following the earnings report the stock price went down -4.566%.

Which hedge fund is a major shareholder of Nyxoah?

Currently, no hedge funds are holding shares in NYXH

Nyxoah Stock Smart Score

Outperform

Fundamentals

Return on Equity

-78.11%

Trailing 12-Months

Asset Growth

-13.94%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Nyxoah

Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. It offers Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. The company was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

Nyxoah (NYXH) Earnings & Revenues

Historic Earnings Reports

NYXH Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Neutral

Nyxoah's Q2 2025 earnings call highlighted the significant milestone of FDA approval for the Genio system and strong revenue growth, indicating a positive launch trajectory in the U.S. However, increased operating losses and a reduced cash position, along with a patent lawsuit, present challenges that temper the overall outlook.View all NYXH earnings summaries

NYXH Stock 12 Month Forecast

Average Price Target

$13.58

▲(120.10% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"$5","8":"$8","11":"$11","14":"$14","17":"$17"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":16.886178,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$16.89</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":13.58,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$13.58</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$12.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5,8,11,14,17],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Dec<br/>2024","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.3,8.037398307692307,8.774796615384615,9.512194923076922,10.24959323076923,10.986991538461538,11.724389846153846,12.461788153846154,13.199186461538462,13.93658476923077,14.673983076923077,15.411381384615385,16.14877969230769,{"y":16.886178,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.3,7.783076923076923,8.266153846153847,8.749230769230769,9.232307692307693,9.715384615384615,10.198461538461538,10.681538461538462,11.164615384615384,11.647692307692306,12.13076923076923,12.613846153846154,13.096923076923076,{"y":13.58,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.3,7.661538461538461,8.023076923076923,8.384615384615385,8.746153846153845,9.107692307692307,9.46923076923077,9.830769230769231,10.192307692307692,10.553846153846154,10.915384615384616,11.276923076923076,11.638461538461538,{"y":12,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":9.41,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.03,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.31,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.22,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.55,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.04,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.87,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.01,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.64,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.55,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.3,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >